STOCK TITAN

Omeros Corporation (OMER) Stock News

OMER NASDAQ

Omeros Corporation develops and commercializes protein and small-molecule therapeutics for large-market and orphan indications, with emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its news centers on YARTEMLEA (narsoplimab-wuug), an FDA-approved MASP-2 lectin pathway inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adult and pediatric patients aged two years and older.

Recurring updates also cover U.S. commercialization, reimbursement coding, transplant-medicine presentations, operating and financial results, and pipeline work including OMS1029, a long-acting MASP-2 inhibitor, and OncotoX-AML, an oncology therapeutic platform targeting acute myeloid leukemia.

Rhea-AI Summary

Omeros (OMER) reported third-quarter 2026 YARTEMLEA net revenue of $35.9 million, as sales growth accompanied positive operating cash flow. Net revenue rose 26% from the second quarter; gross revenue increased 30% to $41.8 million. GAAP net loss was $57.4 million, or $0.79 per share, including a $62.0 million non-cash loss primarily tied to convertible-note derivative adjustments. Adjusted net income was $4.7 million versus $1.8 million in the second quarter.

Operating cash flow was $13.3 million, with $95.3 million in cash and short-term investments at September 30. July repurchases retired $30.5 million of convertible-note principal for $60.2 million plus interest, leaving approximately $40.3 million outstanding. In October, the European medicines advisory committee reaffirmed its negative opinion on narsoplimab for transplant-associated thrombotic microangiopathy. Omeros expects additional clinical studies to begin in late 2026 or early 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Omeros (OMER) will release its third-quarter 2026 financial results after market close on November 16, 2026. Management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the results and recent developments. A replay will be available for 90 days on the company’s Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
earnings date
-
Rhea-AI Summary

Omeros (OMER) received a negative European regulatory opinion after re-examination of its application for narsoplimab to treat a stem-cell transplant complication. The European Medicines Agency’s Committee for Medicinal Products for Human Use maintained its June 2026 negative opinion on treatment for transplant-associated thrombotic microangiopathy (TA-TMA).

Narsoplimab, branded YARTEMLEA, received FDA approval in December 2025 for patients two years and older and is being commercialized in the U.S. Omeros plans to license EU commercialization rights if authorization is granted. Citing increasing U.S. commercial supply demand, it intends to end its compassionate-use program and is pursuing reimbursed named-patient access where permitted in Europe and other regions. Omeros plans studies in acute respiratory distress syndrome and prevention of high-risk pediatric TA-TMA later in 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.78%
Tags
none
Rhea-AI Summary

Omeros (Nasdaq: OMER) reported second‑quarter 2026 net product sales of $28.5 million, all from YARTEMLEA, whose gross revenue rose 190% quarter‑over‑quarter to $32.2 million from $11.1 million. Gross‑to‑net adjustments were about 11.5%.

GAAP net income was $13.2 million, or $0.18 per diluted share, versus a $25.4 million loss a year earlier, aided by an $11.5 million non‑cash gain from 2029 note remeasurement. Non‑GAAP adjusted net income was $1.8 million ($0.02 per share), compared with a $17.1 million loss in first‑quarter 2026.

Omeros ended June 30, 2026 with $132.0 million in cash and short‑term investments and generated $4.1 million of operating cash in the quarter. The company repurchased $30.5 million principal of its 2029 notes for $60.2 million, cutting remaining principal to $40.3 million, eliminating $8.6 million of future interest and reducing potential dilution by about 5 million shares. Omeros also bought back 0.5 million shares in Q2 and 0.8 million year‑to‑date at an average $11.70 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.55%
Tags
-
Rhea-AI Summary

Omeros (NASDAQ: OMER) will release its financial results for the second quarter of 2026 on Wednesday, August 12, 2026, after market close. Management will hold a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) the same day to review recent developments, highlights, and the quarter’s financial performance.

Investors can access the live webcast via the “Upcoming Events” section of the Omeros Investor Relations website, with a replay available for 90 days in “Archived Events.” According to the company, Omeros is transitioning to a new earnings call platform hosted by Q4, and participants are advised to allow extra time to log in.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
earnings date
-
Rhea-AI Summary

Omeros (Nasdaq: OMER) announced that the Centers for Medicare & Medicaid Services granted New Technology Add-On Payment (NTAP) status for YARTEMLEA (narsoplimab-wuug) in the FY 2027 Hospital Inpatient Prospective Payment System Final Rule. Effective October 1, 2026, eligible U.S. hospitals treating Medicare patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) using YARTEMLEA will receive up to $287,079 in additional Medicare reimbursement per eligible inpatient.

According to Omeros, NTAP payments go to hospitals and do not change the amount it receives for YARTEMLEA. YARTEMLEA is described as the first and only FDA-approved treatment for TA-TMA and the only approved inhibitor of the lectin pathway of complement, targeting MASP-2. The company highlights its broader pipeline in complement-mediated diseases, oncology, and addictive disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
none
Rhea-AI Summary

Omeros (Nasdaq: OMER) reported that EMA’s CHMP issued a negative opinion on its MAA for narsoplimab (YARTEMLEA) in TA-TMA. The company plans to request re-examination and AHEG review.

YARTEMLEA received FDA approval in December 2025 for TA-TMA patients ≥2 years and is supplied via a global compassionate use program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.12%
Tags
none
-
Rhea-AI Summary

Omeros (Nasdaq: OMER) will host a live webcast of its virtual Annual Meeting of Shareholders on Thursday, June 18, 2026, at 10:00 a.m. Pacific Time via www.virtualshareholdermeeting.com/OMER2026.

Only shareholders of record as of April 17, 2026 may vote; a replay will be available on the investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
none
-
Rhea-AI Summary

Omeros (Nasdaq: OMER) reported first-quarter 2026 results, driven by the January U.S. launch of YARTEMLEA. Gross product sales were $11.1 million, with net sales of $9.9 million. Reported net income was $56.1 million ($0.78/share), including a $73.1 million non-cash gain from 2029 note derivatives; non-GAAP adjusted net loss was $17.1 million ($0.24/share). Cash and short-term investments totaled $135.3 million. The company fully repaid its 2026 notes and now has $70.8 million of 2029 notes outstanding. CMS assigned a permanent J-code for YARTEMLEA effective July 1, 2026, and proposed NTAP status, with a final decision expected in August and potential effectiveness October 1, 2026. EMA review of the YARTEMLEA MAA continues with a mid-2026 decision expected.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
Rhea-AI Summary

Omeros (NASDAQ: OMER) will release its first quarter 2026 financial results on Wednesday, May 13, 2026, after market close.

Management will host a conference call and webcast at 4:30 p.m. ET to review recent developments and financial results, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
earnings date

FAQ

What is the current stock price of Omeros (OMER)?

Omeros (OMER) last closed at $16.68.

What is the market cap of Omeros (OMER)?

The market cap of Omeros (OMER) is approximately $1.2B.